Literature DB >> 2021034

Bacillus Calmette-Guérin (BCG): mechanism of action in superficial bladder cancer.

T L Ratliff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2021034     DOI： 10.1016/0090-4295(91)80127-s

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  7 in total

1.  Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.

Authors:  Y Luo; X Chen; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Extracellular matrix and integrin composition of the normal bladder wall.

Authors:  C B Wilson; J Leopard; D A Cheresh; R M Nakamura
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

3.  Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy.

Authors:  Laurence M Wood; Zhen-Kun Pan; Vafa Shahabi; Yvonne Paterson
Journal:  Cancer Immunol Immunother       Date:  2010-03-06       Impact factor: 6.968

4.  Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients.

Authors:  P Conti; M Reale; M Nicolai; R C Barbacane; F C Placido; R Iantorno; R Tenaglia
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

Review 5.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

6.  Clinical and immunological effect of intravesical interleukin-2 on superficial bladder cancer.

Authors:  A M Nouri; R Hyde; R T Oliver
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

7.  Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

Authors:  R Nadler; Y Luo; W Zhao; J K Ritchey; J C Austin; M B Cohen; M A O'Donnell; T L Ratliff
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.